UCB acquires Candid Therapeutics to strengthen portfolio

Belgian pharmaceutical group UCB announced the acquisition of biotech Candid Therapeutics, confirming its external growth strategy.

Published 11sem1 sourceNotable

≈ 18sSpeed

The fact

This acquisition allows UCB to accelerate development in key strategic therapeutic areas.

The deal illustrates persistent consolidation dynamics in the European biopharmaceutical sector.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on May 5, 2026